Qalsody (Tofersen) Patent Expiration, LOE Window & CMS Spending

Qalsody (Tofersen) by Biogen: FDA Orange Book core substance LOE 2035-04-01, 0 AB generics, $1.8M 2024 CMS Part D & Medicaid spend, and $14,230 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiogen
FDA Application & PathwayN215887 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-04-01
Last Listed Patent or Exclusivity Date2035-04-01
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.8M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$690K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($14,230 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.